AR and prostate carcinoma: LNCaP95 cells are a model of castration-resistant prostate cancer that demonstrate sustained AR expression, cellular plasticity (Hu et al., 2012) and acquire enzalutamide resistance through activation of the transcription factor Snail (Ware et al., 2016).